Markets are now in their Santa phase. Expect rallies with brief interruptions for consolidation or p...
Murphy: Biotech at a Discount
11/22/2002 12:00 am EST
Mutual funds trade at the value of their net assets. However, a closed-end fund—like a stock—can trade at either a discount or premium to its net assets, based on investor optimism or pessimism regarding the future value of the fund's holdings. For those seeking exposure to the biotech sector, Michael Murphy, editor of Health Investing, recommends a closed-end fund that is trading at a 20% discount to its assets.
“Most small- and mid-cap biotechs are unprofitable and risky, and as such I won’t recommend early-stage companies. Nevertheless, I want you to have some exposure to these companies. The way to do that while minimizing risk is with biotech mutual funds that give us decent diversification. H&Q Life Sciences Investors (
“The fund is allowed to invest in private company venture capital investments. It currently holds 30% of its portfolio in these restricted securities. The fund can invest as much as 40% in this sector. These investments are carried at cost or the valuation set for a subsequent financing round. Yet many of them will be worth more than that in the next round of financing, or an initial public offering, or merger. You get a double discount on these—the low valuation is part of the current net asset value, and then you buy at a 20% discount to that.
“HQL is mostly invested in biotechnology, almost 50%. The current cash position is abnormally high at 20%, but management has been cautious during this downturn. The fund has a September fiscal year, and as of the end of the June quarter, the largest holdings were Gilead Sciences, Martek Biosciences, Endocardial Solutions, Cubist Pharmaceuticals, and CV Therapeutics.
“Overall, investors can gain as a result of appreciation in the net asset value of these biotech holdings. Investors can also benefit if the discount to net asset value shrinks. We note that in a bull market, the fund can even trade at a premium to its net assets. Meanwhile, investors get an 8% or better annual distribution. Together, these factors make this an excellent investment. Buy HQL at a discount of 20% or more. (To calculate the discount, divide the closing price of HQL by the net asset value on that day and subtract 1.) I think the fund can trade up to $14.50 by the end of 2003, plus pay its 8% distribution. That adds up to a nice 25% return by the end of next year.”
At worst the tax cuts will validate current market valuations, says Tom Essaye. At best they’l...
Political news is back driving markets at least until the FOMC today and ECB Thursday. Markets are w...